Altimmune (ALT) announced an update on their ongoing clinical study.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Altimmune’s IMPACT trial, officially titled “A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Pemvidutide in Non-Cirrhotic Subjects With Nonalcoholic Steatohepatitis (NASH),” aims to see whether its lead drug can resolve NASH and improve liver scarring. This matters because NASH is a large, underserved market with no widely adopted drug treatments, so any clear sign of benefit can shift expectations for Altimmune’s pipeline value and partnership potential.
The study is testing pemvidutide, a drug given by subcutaneous injection, against a placebo. Pemvidutide is designed to treat NASH by improving liver health and metabolic markers that drive the disease, while the placebo arm provides a clean benchmark to gauge real drug effects.
The trial uses a randomized, parallel-group design, meaning participants are assigned by chance to one of three arms and stay there for the study. It is double-blind and placebo-controlled, with patients, doctors, and assessors all unaware of who gets pemvidutide or placebo, which reduces bias. The primary goal is treatment, focusing on how well pemvidutide works and how safe it is in people with NASH who do not yet have cirrhosis.
The study was first submitted on July 24, 2023, marking the formal start of the clinical record. The trial status is now listed as completed, and the most recent update was posted on December 24, 2025, signaling that key data collection is done and the record has been refreshed. Final results have not yet been posted to the registry, so investors are still waiting for detailed outcomes.
For investors, the completion of this Phase 2 NASH trial is a key milestone that can drive Altimmune (ALT) volatility as top-line data emerge. Positive results would support pemvidutide’s value in a competitive NASH field that includes players like Madrigal and larger pharma companies, potentially boosting ALT’s share price and improving its leverage in future licensing or funding talks. Conversely, any safety or efficacy concerns could pressure the stock and dampen sentiment toward Altimmune’s broader metabolic platform. With NASH still an open race, this update keeps Altimmune in the conversation as a contender in a high-value liver disease market.
The IMPACT trial of pemvidutide in NASH is now completed and recently updated, with further details available on the ClinicalTrials portal.
To learn more about ALT’s potential, visit the Altimmune drug pipeline page.